WallStSmart

Apollo Global Management LLC Class A (APO)vsBlackRock Health Sciences Trust II (BMEZ)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

APO leads profitability with a 3.7% profit margin vs 0.0%. BMEZ trades at a lower P/E of 5.7x. APO earns a higher WallStSmart Score of 46/100 (D+).

APO

Hold

46

out of 100

Grade: D+

Growth: 4.7Profit: 5.0Value: 5.0Quality: 3.0
Piotroski: 1/9Altman Z: 0.03

BMEZ

Avoid

30

out of 100

Grade: F

Growth: 3.3Profit: 4.0Value: 6.7Quality: 6.0
Piotroski: 3/9

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

APO3 strengths · Avg: 8.3/10
Market CapQuality
$74.23B9/10

Large-cap with strong market position

PEG RatioValuation
0.688/10

Growing faster than its price suggests

Free Cash FlowQuality
$1.62B8/10

Generating 1.6B in free cash flow

BMEZ2 strengths · Avg: 10.0/10
P/E RatioValuation
5.7x10/10

Attractively priced relative to earnings

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Areas to Watch

APO4 concerns · Avg: 2.5/10
Profit MarginProfitability
3.7%3/10

3.7% margin — thin

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

P/E RatioValuation
81.5x2/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
-9.2%2/10

Revenue declined 9.2%

BMEZ4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$904.39M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
5.7%3/10

ROE of 5.7% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : APO

The strongest argument for APO centers on Market Cap, PEG Ratio, Free Cash Flow. PEG of 0.68 suggests the stock is reasonably priced for its growth.

Bull Case : BMEZ

The strongest argument for BMEZ centers on P/E Ratio, Debt/Equity.

Bear Case : APO

The primary concerns for APO are Profit Margin, Piotroski F-Score, P/E Ratio. A P/E of 81.5x leaves little room for execution misses. Thin 3.7% margins leave little buffer for downturns.

Bear Case : BMEZ

The primary concerns for BMEZ are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

BMEZ is growing revenue faster at 0.0% — sustainability is the question.

APO generates stronger free cash flow (1.6B), providing more financial flexibility.

Monitor ASSET MANAGEMENT industry trends, competitive dynamics, and regulatory changes.

Bottom Line

APO scores higher overall (46/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Apollo Global Management LLC Class A

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

Apollo Global Management LLC Class A (APO) is a premier global alternative investment firm with expertise in private equity, credit, and real estate, targeting diverse sectors including healthcare, financial services, and technology. The firm employs a rigorous investment strategy, utilizing its extensive industry knowledge and operational acumen to optimize portfolio performance and promote sustainable growth. With a strong commitment to identifying high-potential investment opportunities in both developed and emerging markets, Apollo strives to deliver attractive risk-adjusted returns, underpinned by substantial capital resources and innovative investment methodologies.

BlackRock Health Sciences Trust II

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

BlackRock Health Sciences Trust II (BMEZ) is a closed-end fund designed to deliver high total returns by investing in a diversified portfolio focused primarily on the health sciences sector, encompassing pharmaceuticals, biotechnology, and medical devices. Backed by BlackRock's extensive investment management experience, BMEZ seeks to capitalize on substantial growth prospects driven by demographic shifts and increasing healthcare spending. The fund's disciplined and strategic investment approach positions it as a compelling choice for institutional investors looking to enhance their portfolios while navigating the dynamic and innovative landscape of the health sciences industry.

Want to dig deeper into these stocks?